Memorial Sloan Kettering establishes MSKCC India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Memorial Sloan Kettering Cancer Center has established MSKCC India to provide cancer patients in India with access to the institution’s oncologists, research, clinical trials, and education. 

MSKCC India will provide remote opinions via video or written consultations. A Memorial Sloan Kettering Cancer Center oncologist who specializes in a patient’s form of cancer will review their medical records, test results, and other materials and provide a comprehensive written opinion, meet with the patient virtually using telemedicine technology, or speak with the patient’s local oncologist about their diagnosis and care plan. 

In some cases, they may recommend that the patient travel to receive care at Memorial Sloan Kettering Cancer Center in New York City. Specific services include:

  • Pathology diagnosis
  • Radiology scan reviews
  • Next-generation sequencing (MSK-IMPACTTM) of a patient’s tumor and treatment recommendations
  • Travel assistance to New York City

Memorial Sloan Kettering Cancer Center has partnered with iCliniq, a global telemedicine provider based in India. 

MSKCC India will open a physical location in Chennai, centrally located for patients and staff members. This location will serve as a hub for medical staff who will help patients coordinate written or virtual consultations, and they will be able to communicate in English, Hindi, Urdu, Tamil, Telugu and Kannada. 

If necessary, employees will be able to collect medical records from patients’ homes, making the process more convenient for those utilizing this service. Patients across India will be able to obtain a remote opinion from experts at Memorial Sloan Kettering Cancer Center in the comfort of their home or any internet-enabled location without traveling to MSKCC India in Chennai.

Patients in India now can visit in.mskcc.org/india to learn more about MSKCC India and how to schedule a consultation with a Memorial Sloan Kettering Cancer Center expert.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login